ArticleAmerican journal of preventive cardiology2026
Cardiovascular-kidney-metabolic syndrome stages and increased risk of all-cause and cause-specific mortality in UK Biobank.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From conceptual emergence to multidisciplinary expansion: a bibliometric and knowledge mapping analysis of cardiovascular-kidney-metabolic syndrome research.Frontiers in endocrinology · 2026Pooled it
- Association of cardiovascular-kidney-metabolic syndrome with blinding eye diseases: insights from a UK Biobank cohort analysis.Eye (London, England) · 2026Article
- Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.International journal of molecular sciences · 2026Review
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- Epidemiology of cardiovascular disease and diabetes in 2026: expanding prevalence, escalating costs, and the limits of contemporary prevention.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Lowering barriers Not the bar: Redefining the role of American Journal of Preventive Cardiology in the next era.American journal of preventive cardiology · 2026Article
- Article
- Association of accelerometer-measured physical activity and the risk of incident cardiovascular diseases within the AHA cardiovascular-kidney-metabolic syndrome 0-4 framework: a prospective cohort of the UK Biobank.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular-kidney-metabolic (CKM) syndrome poses a critical challenge for public health. However, its association with mortality risk remain inadequately characterized. Methods: 282,952 participants at baseline from the UK Biobank were monitored until November 12, 2021. Cox regression analyses evaluated the associations between CKM stages and the risk of all-cause and cause-specific mortality, including cardiovascular diseases (CVD), cancer, respiratory diseases, and digestive system diseases. Results: Over a median follow-up of 12.7 years, 16,834 deaths occurred, including 15.8% from CVD, 50.3% from cancer, 6.0% from respiratory diseases, 3.6% from digestive system diseases, and 24.3% from other causes. The risk of all-cause, cancer, CVD, respiratory, and digestive mortality increased with advancing CKM stages ( Conclusions: CKM stages are strongly associated with increased all-cause and cause-specific mortality. Early identification and intervention in CKM syndrome patients could be crucial for reducing premature mortality and improving public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.